An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases.
J Interferon Cytokine Res
; 44(4): 143-157, 2024 Apr.
Article
em En
| MEDLINE
| ID: mdl-38421721
ABSTRACT
Interleukin-2 (IL-2) is a cytokine that acts in dual and paradoxical ways in the immunotherapy of cancers and autoimmune diseases. Numerous clinical trial studies have shown that the use of different doses of this cytokine in various autoimmune diseases, transplantations, and cancers has resulted in therapeutic success. However, side effects of varying severity have been observed in patients. In recent years, to prevent these side effects, IL-2 has been engineered to bind more specifically to its receptors on the cell surface, decreasing IL-2 toxicities in patients. In this review article, we focus on some recent clinical trial studies and analyze them to determine the appropriate dose of IL-2 drug with the least toxicities. In addition, we discuss the engineering performed on IL-2, which shows that engineered IL-2 increases the specificity function of IL-2 and decreases its adverse effects.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
J Interferon Cytokine Res
Ano de publicação:
2024
Tipo de documento:
Article